Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Anti-Cancer Agents in Medicinal Chemistry

• Publication date

  2017-06-30

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/1871520616666160928153342PMID 27697038
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

  2015cited by this paper
• Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

  2015cited by this paper
• The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.

  2015cited by this paper
• Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

  2014cited by this paper
• Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.

  2014cited by this paper
• Bruton’s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib

  2014cited by this paper
• Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

  2014cited by this paper
• Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

  2014cited by this paper
• Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.

  2014cited by this paper
• Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.

  2014cited by this paper
• Incorporating targeted agents into future therapy of chronic lymphocytic leukemia.

  2014cited by this paper
• Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.

  2013cited by this paper
• Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

  2013cited by this paper
• The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

  2012cited by this paper
• Nurture versus nature: the microenvironment in chronic lymphocytic leukemia.

  2011cited by this paper
• Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

  2011cited by this paper
• The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

  2011cited by this paper
• Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

  2011cited by this paper
• The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

  2010cited by this paper
• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

  2010cited by this paper
• Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

  2008cited by this paper
• Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

  2008cited by this paper
• In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.

  2002cited by this paper
• Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course

  2002cited by this paper
• The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases

  1993cited by this paper

• Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases.

  2023cites this paper
• Combining structure-based pharmacophore modeling and machine learning for the identification and in vitro validation of novel BTK inhibitors.

  2022cites this paper
• A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature

  2021cites this paper
• Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors

  2021cites this paper